VOYXACT®  – Effect on Urinary Protein-to-Creatinine Ratio
This information is provided as a professional courtesy for general educational and informational purposes only. It is not intended to provide medical advice for a particular patient. The content may contain information about Otsuka products or uses that has not been approved by the U.S. Food and Drug Administration. Otsuka does not recommend the use of its products outside of the approved prescribing information. Do not copy or distribute without permission. Please refer to the link below to view the complete prescribing information. If you would like to discuss a medical inquiry or require additional information, please call 1-800-441-6763. Additionally, to report any suspected adverse event or a product quality complaint related to an Otsuka product, please call 1-800-438-9927. By accessing these files, I am confirming that I am a U.S. healthcare professional or an authorized member of the Otsuka Medical team.
This letter may contain information that is not included in the Prescribing Information for VOYXACT® (sibeprenlimab-szsi) injection, for subcutaneous use1. Please refer to the Prescribing Information for the approved label indication and important safety information.
This standard response document is best viewed on Chrome or Firefox. Free downloads are available here:
Click to download Chrome
Click to download Firefox